# A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis

> **NCT07660848** · PHASE2 · RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Metabolic Dysfunction-Associated Steatohepatitis (MASH)

## Interventions

- **DRUG:** HRS-4729 Injection
- **DRUG:** HRS9531 Injection
- **DRUG:** HRS-4729 Injection Placebo
- **DRUG:** HRS9531 Injection Placebo

## Key facts

- **NCT ID:** NCT07660848
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-14
- **Primary completion:** 2028-03
- **Final completion:** 2028-07
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660848, "A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07660848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*